Anne Wojcicki's winning bid to reclaim control of 23andMe doesn't necessarily end the fight over what happens to the DNA of 15 million people collected by the bankrupt consumer genomics company.

A nonprofit led by the co-founder and former CEO of 23andMe outbid competitors for nearly all of the company’s assets.

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...

Privacy and information commissioners from Canada and the U.K. will reveal the findings of their investigation into the 23andMe data breach.

UK regulators on Tuesday fined 23andMe 2.31 million pounds ($3.1 million) for data privacy violations stemming from the ...

A 23andMe booth at a genealogical event. The Canadian and British commissioners found the company did not have adequate ...

"There are only a handful of people in the world who have experience in running a direct-to-consumer genetic testing company ...

Regeneron Pharmaceuticals had previously agreed to acquire the company for $256 million. TTAM’s higher bid and added consumer protections ultimately led the board’s special committee to select it as ...

Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...

With plenty of GLP-1 money to spend, Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for ...

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

The stratospheric balloons fly higher than airplanes, allowing them to map large disaster areas faster and cheaper than planes or drones.